Press Releases

OncoSec Medical to Present at Two Events in December

SAN DIEGO-- OncoSec Medical Inc. (OTCQB: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, will present at two events in December. The Company’s agenda includes high-profile scientific and investment conferences, coming on the heels of a recent key milestone announcement.

LD Micro Conference

Jordyn Kopin, Associate Director of Corporate Communications, will present a corporate overview of the Company at the 7th annual LD Micro Conference, taking place December 2-4, 2014 at the Luxe Sunset Boulevard Hotel in Los Angeles, California.

LD Micro is an investment newsletter firm that focuses on finding undervalued companies in the micro-cap space. Since 2002, the firm has published reports on select companies throughout the year. The firm also hosts the LD Micro Invitational. It is a non-registered investment advisor. For more information, please contact 408-457-1042 or visit www.ldmicro.com.

Melanoma Bridge 2014

OncoSec Medical will present new data from clinical studies evaluating the Company’s ImmunoPulse immunotherapy in patients with melanoma at Melanoma Bridge 2014. The event is scheduled to take place at the Royal Continental Hotel in Naples, Italy from December 3-6, 2014. For more information, click here.

Melanoma Bridge 2014 aims to achieve a broad-based participation by various groups and societies sharing a clinical or basic interest in the immunology and the biology of the cancer microenvironment. The Scientific Board of Melanoma Bridge includes well-known experts from around the world covering a variety of different areas and specialties. The event is being jointly organized by Istituto Nazionale Tumori Fondazione "G. Pascale", Fondazione Melanoma Onlus and Sidra Medical and Research Center, together with the Society for Immunotherapy of Cancer (SITC). For more information, please visit: http://www.melanomabridge.org

About OncoSec Medical

OncoSec Medical Inc. is a biopharmaceutical company developing its investigational ImmunoPulse intratumoral cancer immunotherapy. OncoSec Medical's core technology is designed to enhance the local delivery and uptake of DNA IL-12 and other DNA-based immune-targeting agents. Clinical studies of ImmunoPulse have demonstrated an acceptable safety profile and preliminary evidence of anti-tumor activity in the treatment of various skin cancers, as well as the potential to initiate a systemic immune response without the systemic toxicities associated with other treatments. OncoSec's lead program evaluating ImmunoPulse for the treatment of metastatic melanoma is currently in Phase 2 development, and is being conducted in collaboration with several prominent academic medical centers. As the company continues to evaluate ImmunoPulse in its current indications, it is also focused on identifying and developing new immune-targeting agents, investigating additional tumor indications, and evaluating combination-based immunotherapy approaches. For more information, please visit www.oncosec.com.

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such “forward-looking statements.” Forward-looking statements are based on management’s current preliminary expectations and are subject to risks and uncertainties, which may cause our results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include our ability to raise additional funding, our ability to acquire, develop or commercialize new products, uncertainties inherent in pre-clinical studies and clinical trials, unexpected new data, safety and technical issues, competition, and market conditions. These and additional risks and uncertainties are more fully described in OncoSec Medical’s filings with the Securities and Exchange Commission. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. OncoSec Medical disclaims any obligation to update any forward-looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.

Investor Relations:
OncoSec Medical Inc.
Jordyn Kopin, 855-662-6732
investors@oncosec.com
or
Public Relations:
Dian Griesel Int’l.
Laura Radocaj, 212-825-3210
lradocaj@dgicomm.com

Source: OncoSec Medical Inc.